SN-38 LIPID COMPLEXES AND METHODS OF USE

(19)

(11)

EP 1 355 634 B8

(12)	CORRECTED EUROPEAN PATENT SPECIFICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 1 (W1 B1)

(48)	Corrigendum issued on:
	04.03.2009 Bulletin 2009/10

(45)	Mention of the grant of the patent:
	05.11.2008 Bulletin 2008/45

(21)	Application number: 01994079.0

(22)	Date of filing: 09.11.2001

(51)

International Patent Classification (IPC):

A61K 9/48^(2006.01)
A61K 9/133^(2006.01)

A61K 9/127^(2006.01)
A61K 31/4745^(2006.01)

(86)	International application number:
	PCT/US2001/043325

(87)	International publication number:
	WO 2002/058622 (01.08.2002 Gazette 2002/31)

(54)	SN-38 LIPID COMPLEXES AND METHODS OF USE SN-38-LIPIDKOMPLEXE UND VERFAHREN ZU IHRER VERWENDUNG COMPLEXES LIPIDIQUES A BASE DE SN-38 ET PROCEDES D'UTILISATION

(84)	Designated Contracting States:
	AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR
	Designated Extension States:
	AL LT LV MK RO SI

(30)

Priority:

09.11.2000 US 247306 P

(43)	Date of publication of application:
	29.10.2003 Bulletin 2003/44

(73)	Proprietor: Neopharm, Inc.
	Lake Bluff IL 60044 (US)

(72)	Inventors:
	AHMAD, Imran Wadsworth, IL 60083 (US) ZHANG, Jia-Ai (Allen) Vernon Hills, IL 60601 (US) RAHMAN, Aquilur Potomac, MD 20854 (US)

(74)	Representative: Wössner, Gottfried et al
	HOEGER, STELLRECHT & PARTNER Patentanwälte Uhlandstrasse 14 c 70182 Stuttgart 70182 Stuttgart (DE)

(56)

References cited: :

WO-A-00/23052
WO-A-95/08986
US-A- 5 552 156
US-A- 6 056 973
US-B1- 6 291 676

WO-A-93/18751
WO-A-99/13816
US-A- 5 834 012
US-A- 6 096 336

LUNDBERG B B: "BIOLOGICALLY ACTIVE CAMPTOTHECIN DERIVATIVES FOR INCORPORATION INTO LIPOSOME BILAYERS AND LIPID EMULSIONS" ANTI-CANCER DRUG DESIGN, BASINGSTOKE, GB, vol. 13, no. 5, 1998, pages 453-461, XP000878681 ISSN: 0266-9536
SADZUKA Y: "Effective prodrug liposome and conversion to active metabolite" CURRENT DRUG METABOLISM, BENTHAM SCIENCE PUBLISHERS,, US, vol. 1, no. 1, 2000, pages 31-48, XP002954303 ISSN: 1389-2002
SADZUKA Y ET AL: "EFFECT OF LIPOSOMALIZATION ON THE ANTITUMOR ACTIVITY, SIDE-EFFECTS AND TISSUE DISTRIBUTION OF CPT-11" CANCER LETTERS, NEW YORK, NY, US, vol. 127, no. 1/2, 15 May 1998 (1998-05-15), pages 99-106, XP000878677 ISSN: 0304-3835
GOKHALE PC ET AL: "AN IMPROVED METHOD OF ENCAPSULATION OF DOXORUBICIN IN LIPOSOMES: PHARMACOLOGICAL, TOXIGOLOGICAL AND THERAPEUTIC EVALUATION" BRITISH JOURNAL OF CANCER, LONDON, GB, vol. 74, no. 1, July 1996 (1996-07), pages 43-48, XP000961424 ISSN: 0007-0920
BURKE T G ET AL: "Lipid bilayer partitioning and stability of camptothecin drugs" BIOCHEMISTRY, AMERICAN CHEMICAL SOCIETY. EASTON, PA, US, vol. 32, no. 20, 25 May 1993 (1993-05-25), pages 5352-5364, XP002288627 ISSN: 0006-2960
EMERSON D L: "Liposomal delivery of camptothecins" PHARMACEUTICAL SCIENCE AND TECHNOLOGY TODAY, ELSEVIER TRENDS JOURNALS, CAMBRIDGE,, GB, vol. 3, no. 6, 1 June 2000 (2000-06-01), pages 205-209, XP002235822 ISSN: 1461-5347

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).